Abstract Acute generalized exanthematous pustulosis (AGEP) and generalized pustular psoriasis (GPP) are rare pustular skin disorders with systemic involvement. IL-17A/ F is a proinflammatory cytokine involved in various neutrophilic inflammatory disorders. Here we show that IL-17A/F is highly expressed by innate immune cells such as neutrophils and mast cells in both AGEP and GPP.
Introduction
Acute generalized exanthematous pustulosis (AGEP) is a rare drug-induced skin reaction. It is characterized by an acute erythematous rash with numerous sterile pustules, accompanied by fever and neutrophilia [18] . Drug specific T cells are implicated in pathogenesis of AGEP, some of which have been shown to exhibit a phenotype consistent with Th17 cells [1, 15, 16] .
Generalized pustular psoriasis (GPP) is characterized by recurrent eruptions of sterile pustules on erythematous skin, high-grade fever and neutrophilia. In GPP and in a subset of AGEP, mutations of the IL-36 receptor antagonist (IL-36Ra) have been shown to lead to unregulated secretion of inflammatory cytokines [10] .
IL-17A/F and Th17 cells have been identified as key players in the pathogenesis of auto-inflammatory disease. IL-17A/F is a potent inducer of tissue inflammation and neutrophil recruitment [12] . Although the key role of IL-17A/F/ Th17 cells in the pathogenesis of plaque psoriasis is well described [5] , its expression in AGEP and GPP has not been studied in detail. Therefore, we sought to investigate the expression and distribution of IL-17A/F and its cellular source in AGEP and GPP in comparison to normal human skin.
Materials and methods

Samples from patients
The study was approved by the local Medical Ethics Committee. After informed consent, tissue samples were obtained from patients with AGEP (n = 8) and GPP (n = 8). Diagnosis was based on the EuroSCAR validation score [2] for AGEP and on clinical and histological features for GPP. Normal skin was obtained from healthy individuals who underwent surgery for esthetic reasons (n = 7, median age 50 years).
The culprit drugs identified in our patients included amoxicillin-clavulanic acid (2 patients), terbinafine (2 patients), amoxicillin, clarithromycin, clindamycin and ibuprofen. GPP samples were from 8 patients (5 female and 3 male) with the median age of 58 years (range 22-89 years).
Immunohistochemistry and immunofluorescence
Tissue sections from formalin-fixed, paraffin-embedded blocks were used for immunohistochemical and immunofluorescence staining as previously described [17, 22] .
Goat anti-human IL-17A/F (AF-317-NA, R&D), rabbit anti-human CD3 (A0452, DAKO), mouse anti-human CD68 (EBM11, DAKO), mouse anti-human CD66b (555723, Becton-Dickinson), and rabbit anti-human mast cell tryptase (sc-32889, Santa Cruz) were used. For detecting IL-17A/F a goat HRP polymer kit (GHP516H, Biocare Medical) was used. For double immunohistochemistry both the goat HRP polymer kit and MACH4 Universal mouse/rabbit AP-Polymer Kit (M4U536H, Biocare Medical) were used.
IL-17A/F was detected by immunofluorescence using either donkey anti-goat/Alexa Fluor 488 (A-11055) or rabbit anti-goat/Alexa Fluor 488 (A-11078). CD3 and mast cell tryptase were detected with donkey anti-rabbit/Alexa Fluor 594 (A-21207), CD68 was detected with a rabbit anti-mouse/Alexa Fluor 594 (A-11062), all from Invitrogen. Eosinophil cationic protein (ECP) was detected with monoclonal mouse anti-human ECP antibody (Pharmacia Diagnostics AB, Sweden) followed by goat anti-mouse IgG2a/Alexa Fluor594 (A21135, Invitrogen).
Quantitative analysis was performed using the digital image analysis system NIS-Elements Software BR 2.30 by two independent observers and 3 HPF/biopsy, as previously described [22] . Papillary dermis was defined as the part of the dermis that is intertwined with the rete ridges of the epidermis and is composed of fine and loosely arranged collagen fibers. The reticular dermis was defined as the part of the dermis under the papillary dermis, composed of dense irregular connective tissue.
In-situ hybridization 35 S-labeled sense and antisense IL-17A/F mRNA probe, 333 bp in length and corresponding to position 143-475 bp of the human IL-17A/F sequence (NM_002190.2), were generated by in vitro transcription (10 999 644 001, Roche). In situ hybridization was performed as previously described [11, 23] .
Results
IL-17A/F positive cells in AGEP, GPP and normal skin
In normal skin, few IL-17A/F ? cells were observed in the upper dermis only (Fig. 1a) . In AGEP, IL-17A/F ? cells were found in subcorneal pustules and, to a lesser extent, in the epidermis near pustules and the upper dermis (Fig. 1b) . Similar findings were seen in GPP (Fig. 1c) . Quantitative analysis of IL-17A/F ? cells confirmed statistically significant differences in IL-17A/F expression between normal skin and AGEP and GPP, respectively (Fig. 1d) .
In situ IL-17A/F mRNA expression To confirm IL-17A/F gene expression in the skin, in situ hybridization was performed (Fig. 1h-j) . IL-17A/F transcript expression was detected in normal skin, AGEP, and GPP. IL-17A/F mRNA co-localized with IL-17A/F protein expression, as detected by immunohistochemical staining in consecutive slides (Fig. 1e-g ), thus confirming IL-17A/ F production in situ.
Double immunostaining
To determine the phenotype of cells expressing IL-17A/F, double immunohistochemical staining was performed with markers for neutrophils (CD66b) or T-lymphocytes (CD3) (Fig. 2a-f) . In both AGEP and GPP, almost all cells in subcorneal pustules were CD66b
? /IL-17A/F ? neutrophils (Fig. 2a, c) . In the epidermis and upper dermis, some IL-17A/F ? /CD66b -cells were seen (Fig. 2a-c) . The few CD3
? cells found in pustules did not co-express IL-17A/F (Fig. 2d, f) . In the dermis, only a few IL-17A/F ? /CD3 ? T cells were observed (Fig. 2e) . Therefore, neutrophils appear to be the main source of IL-17A/F in pustules.
Furthermore, double immunofluorescence analysis was performed using markers for T-lymphocytes (CD3), macrophages and dendritic cells (CD68), mast cells (tryptase) (Fig. 3a-c) and for eosinophils (eosinophil cationic protein; ECP [19] ; Suppl. Fig. 1 ). In both AGEP and GPP, IL-17A/F co-localized frequently with tryptase and CD68, respectively. CD3
? /IL-17A/F ? cells were only scarcely detected, whereas eosinophils where not found to express any IL-17A/F in AGEP.
Discussion
Here we demonstrate on both the mRNA and the protein level that IL-17A/F-expressing cells are significantly In our study, IL-17 expression by neutrophils was assessed by in situ co-localization of both IL-17A/F mRNA and protein with CD66b. In humans, CD66b is expressed constitutively by neutrophils and eosinophils and CD66b expression levels increase upon granulocyte activation [24] . Since neutrophils have been shown to express IL-17A/F after stimulation with IL-6 and IL-23, co-expression of IL-17 found in our study may indicate simultaneous upregulation of CD66b and IL-17 in neutrophils as a consequence of cytokine stimulation by IL-6 and IL-23, both of which are cytokines intimately linked to the pathogenesis of psoriasis [3, 8] . To further confirm IL-17 expression by neutrophils, we excluded relevant expression of IL-17 by CD66b
? eosinophils in AGEP (Suppl. Fig. 1 ). In GPP and normal skin, eosinophils are not part of the immune infiltrate.
In addition to neutrophils and mast cells, macrophages have also been shown to be an important cellular source of IL-17 in murine and human inflammation, most prominently in lung inflammation [4, 20] . Interestingly, we did observe co-localization of IL-17 with CD68
? cells in our immunofluorescence study, indicating that also in human skin inflammation, macrophages and dendritic cells can produce IL-17. However, our data does not rule out the possibility that an uptake of fragments from IL-17-producing cells could also explain the detection of IL-17A/F in macrophages. Further studies are needed to determine the contribution of macrophages to the production of IL-17 in cutaneous inflammation.
AGEP and GPP share clinical, genetic, histological, and immunological features [14] . In accordance with previous data, we show that high in situ expression of IL-17A/F is yet another similarity between the two diseases [6, 13] . IL-17A/F induces IL-36 expression in keratinocytes and IL-36 can induce further proinflammatory signals. Interestingly, loss of function in antagonism of IL-36 based on mutations in the IL-36 receptor antagonist IL-36Ra can cause GPP and IL-36Ra mutations can also be found in a subset of AGEP patients [2, 10, 14] . Therefore, in both GPP and AGEP, activation of keratinocytes by IL-17A/F may enhance local IL-36 expression, which-in the absence of functional antagonism-then drives neutrophil tissue inflammation.
Taken together, our findings position IL-17A/F expression as a common pathogenetic step in both AGEP and GPP, help to explain the similarity of their clinical presentation, and provide a rationale for a therapeutic approach with modern antibodies against IL-17A/F. 
